CompletedNot Applicable

Nanocrystalline Hydroxyapatite Bone Substitute for Treating Periodontal Intrabony Defects

Egypt20 participantsStarted 2018-09-01

Plain-language summary

The present clinical trial included 20 patients (11 females and 9 males, aged 36 to 56 years) suffering from moderate or advanced chronic periodontitis. Subjects were recruited from the outpatient clinic, Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University. This clinical trial was meant to assess clinically and radiographically the possible predictable results regarding the use of nanocrystalline hydroxyapatite bone graft substitute together with open flap debridement versus open flap debridement alone in the treatment of periodontal intrabony defects.

Who can participate

Age range35 Years – 56 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * systemically healthy patients * diagnosed with moderate to advanced chronic periodontitis * periodontal defects with at least one site with probing pocket depth (PPD) ≥ 5mm, clinical attachment loss (CAL) ≥ 4mm and two or three-walled intra-bony defects ≥ 3mm * evidence of intrabony defects using periapical radiographs Exclusion Criteria: * teeth with suprabony defects or 1-wall intrabony defects * pregnant or lactating women * patients taking any medication 3 months prior to the study * patients receiving any periodontal treatment 6 months prior to study initiation * former or current smokers.

What they're measuring

change in probing pocket depth

Timeframe: baseline and after six months

Trial details

NCT IDNCT04643288

SponsorWeam Ahmed Elbattawy

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-11-25

View on ClinicalTrials.gov More Chronic Periodontitis trials